Relblozyl was approved by the FDA for transfusion dependent betathalassemia weeks ahead of its December 4 action date, and the label is "clean and broader" than expected as it includes "all transfusion dependent" beta thalassemia patients, Piper Jaffray analyst Danielle Brill tells investors in a research note. The analyst views the early approval as a signal of the FDA's confidence in Relblozyls's profile. She also sees "positive readthrough" for myelodysplastic syndromes, saying today's approval should mitigate concerns about a potential panel meeting ahead of approval in the indication. Brill reiterates an Overweight rating on Acceleron Pharma with a $73 price target.